Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CBST
- CUSIP: 22967810
- Web: N/A
- 50 Day Moving Avg: $101.00
- 200 Day Moving Avg: $78.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 52.55
- P/E Growth: 0
Frequently Asked Questions for Cubist Pharmaceuticals (NASDAQ:CBST)
What is Cubist Pharmaceuticals' stock symbol?
Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."
How were Cubist Pharmaceuticals' earnings last quarter?
Cubist Pharmaceuticals Inc (NASDAQ:CBST) issued its quarterly earnings data on Tuesday, October, 21st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.54. The company had revenue of $309.20 million for the quarter, compared to analysts' expectations of $305.50 million. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.
Who are some of Cubist Pharmaceuticals' key competitors?
Some companies that are related to Cubist Pharmaceuticals include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Cubist Pharmaceuticals stock?
Shares of Cubist Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cubist Pharmaceuticals' stock price today?
MarketBeat Community Rating for Cubist Pharmaceuticals (NASDAQ CBST)MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cubist Pharmaceuticals stock can currently be purchased for approximately $101.94.
Consensus Ratings for Cubist Pharmaceuticals (NASDAQ:CBST) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cubist Pharmaceuticals (NASDAQ:CBST)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cubist Pharmaceuticals (NASDAQ:CBST)Earnings History by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/21/2014||Q314||$0.04||$0.58||$305.50 million||$309.20 million||View||Listen|
|7/22/2014||Q214||$0.37||$0.23||$299.60 million||$294.40 million||View||N/A|
|4/22/2014||Q114||$0.34||$0.10||$285.24 million||$261.20 million||View||N/A|
|1/23/2014||Q413||$0.33||$0.29||$285.47 million||$299.70 million||View||N/A|
|7/18/2013||Q2 2013||$0.55||$0.42||$254.93 million||$258.80 million||View||N/A|
|4/18/2013||Q1 2013||$0.50||$0.34||$243.55 million||$229.90 million||View||N/A|
|1/23/2013||Q4 2012||$0.48||$0.51||$246.42 million||$245.90 million||View||N/A|
Earnings Estimates for Cubist Pharmaceuticals (NASDAQ:CBST)
Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.94 EPS
Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cubist Pharmaceuticals (NASDAQ:CBST)Insider Trades by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/1/2014||Steven C Gilman||EVP||Sell||48,125||$65.39||$3,146,893.75|| |
|8/19/2014||Gregory Stea||SVP||Sell||38,326||$65.88||$2,524,916.88|| |
|8/18/2014||Nancy J Hutson||Director||Sell||9,000||$65.00||$585,000.00|| |
|8/18/2014||Robert J Perez||COO||Sell||1,003||$63.68||$63,871.04|| |
|7/28/2014||Steven C Gilman||EVP||Sell||40,625||$61.57||$2,501,281.25|| |
|5/15/2014||Michael Bonney||CEO||Sell||3,036||$67.50||$204,930.00|| |
|5/15/2014||Robert Perez||COO||Sell||1,518||$67.50||$102,465.00|| |
|5/15/2014||Steven Gilman||EVP||Sell||16,340||$67.82||$1,108,178.80|| |
|5/14/2014||Michael Bonney||CEO||Sell||3,840||$69.00||$264,960.00|| |
|5/14/2014||Robert Perez||COO||Sell||2,400||$69.00||$165,600.00|| |
|5/14/2014||Steven Gilman||EVP||Sell||1,680||$69.00||$115,920.00|| |
|3/6/2014||Gregory Stea||SVP||Sell||19,889||$79.74||$1,585,948.86|| |
|2/27/2014||Mark Corrigan||Director||Sell||5,000||$80.00||$400,000.00|| |
|2/27/2014||Michael Bonney||CEO||Sell||100,000||$81.25||$8,125,000.00|| |
|2/27/2014||Robert Perez||COO||Sell||30,000||$80.18||$2,405,400.00|| |
|2/20/2014||Michael Bonney||CEO||Sell||3,112||$75.60||$235,267.20|| |
|2/3/2014||Kenneth Bate||Director||Sell||6,250||$72.15||$450,937.50|| |
|1/15/2014||Gregory Stea||SVP||Sell||5,312||$74.90||$397,868.80|| |
|1/15/2014||Robert Perez||COO||Sell||10,000||$74.95||$749,500.00|| |
|1/13/2014||Robert Perez||COO||Sell||10,000||$72.95||$729,500.00|| |
|1/9/2014||Kenneth Bate||Director||Sell||10,000||$70.00||$700,000.00|| |
|1/2/2014||Steven Gilman||EVP||Sell||25,000||$67.82||$1,695,500.00|| |
|12/2/2013||Kenneth Bate||Director||Sell||12,500||$67.63||$845,375.00|| |
|9/9/2013||Martin Rosenberg||Director||Sell||15,472||$65.00||$1,005,680.00|| |
|8/16/2013||Robert Perez||COO||Sell||1,024||$60.55||$62,003.20|| |
|7/31/2013||Gregory Stea||SVP||Sell||33,750||$61.29||$2,068,537.50|| |
|7/26/2013||Nancy J Hutson||Director||Sell||5,000||$53.87||$269,350.00|| |
|7/19/2013||Gregory Stea||SVP||Sell||4,375||$55.00||$240,625.00|| |
|6/3/2013||Kenneth Bate||Director||Sell||2,500||$54.95||$137,375.00|| |
|6/3/2013||Steven C Gilman||EVP||Sell||15,125||$54.49||$824,161.25|| |
|5/24/2013||Mark Corrigan||Director||Sell||14,000||$54.60||$764,400.00|| |
|5/22/2013||J Matthew Singleton||Director||Sell||27,500||$55.48||$1,525,700.00|| |
|5/20/2013||Charles Anthony Laranjeira||SVP||Sell||14,000||$51.43||$720,020.00|| |
|5/20/2013||Michael W Bonney||CEO||Sell||60,000||$50.00||$3,000,000.00|| |
|5/20/2013||Robert J Perez||COO||Sell||15,000||$49.98||$749,700.00|| |
|5/16/2013||Michael W Bonney||CEO||Sell||2,400||$47.88||$114,912.00|| |
|5/16/2013||Robert J Perez||COO||Sell||1,500||$47.88||$71,820.00|| |
|5/16/2013||Steven C Gilman||EVP||Sell||1,201||$48.88||$58,704.88|| |
|5/15/2013||Kenneth Bate||Director||Sell||2,500||$48.41||$121,025.00|| |
|5/15/2013||Michael W Bonney||CEO||Sell||2,979||$48.41||$144,213.39|| |
|5/15/2013||Robert J Perez||COO||Sell||1,490||$48.41||$72,130.90|| |
|5/15/2013||Steven C Gilman||EVP||Sell||1,017||$48.41||$49,232.97|| |
|5/14/2013||Michael W Bonney||CEO||Sell||3,753||$49.18||$184,572.54|| |
|5/14/2013||Robert J Perez||COO||Sell||2,346||$49.18||$115,376.28|| |
|5/14/2013||Steven C Gilman||EVP||Sell||1,135||$49.18||$55,819.30|| |
Headline Trends for Cubist Pharmaceuticals (NASDAQ:CBST)
Latest Headlines for Cubist Pharmaceuticals (NASDAQ:CBST)
Cubist Pharmaceuticals (CBST) Chart for Sunday, May, 28, 2017